Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
AstraZeneca
Mayo Clinic
Tubulis GmbH
Eli Lilly and Company
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Exscientia AI Limited
Radiopharm Theranostics, Ltd
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Tanabe Pharma America, Inc.
BicycleTx Limited
Volastra Therapeutics, Inc.
Immunitas Therapeutics
LigaChem Biosciences, Inc.
Scancell Ltd
A2 Biotherapeutics Inc.
Incyte Corporation
NuCana plc
Medicenna Therapeutics, Inc.
Formation Biologics
Numab Therapeutics AG
Klus Pharma Inc.
DualityBio Inc.
RAPT Therapeutics, Inc.
Cyteir Therapeutics, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
Cancer Research UK
NextCure, Inc.
Icahn School of Medicine at Mount Sinai
Fusion Pharmaceuticals Inc.
Genmab
Nektar Therapeutics
Rubius Therapeutics
Ludwig Institute for Cancer Research
ImmVira Pharma Co. Ltd
Incyte Corporation
Silverback Therapeutics
Incyte Corporation
NKGen Biotech, Inc.
Millennium Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center